Nanobodies targeting cd276 and uses thereof
Patent Information
- Application Number
- CN202411386065.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-30
- Publication Date
- 2026-09-22
- Estimated Expiration
- 2044-09-30
AI Technical Summary
[0004]现有技术的缺点包括:(1)传统的单链或双链抗体,分子量较大,免疫原性强,容易发生重轻链错配的现象,尤其是单链抗体用到CAR-T/NK上,轻重链错配导致CAR结构聚集,从而引起CAR-T/NK自发耗竭,降低CAR-T/NK的功能;(2)针对实体瘤细胞,现有技术(CN114729041A)构建的CAR-T需要在极高的效靶比下(最高50:1)才能发挥较高的肿瘤杀伤效果;(3)现有技术的抗体筛选手段以噬菌体库为主,抗体种类较少
[0058](1)相比传统的抗体,纳米抗体是分子量最小的抗原结合片段,具有可溶性好、结构简单稳定、组织穿透力强、低免疫原性等特点。尤其是应用到CAR-T/NK上,由于其亲水性较强,因此基于纳米抗体的CAR几乎无聚集的风险。另外由于纳米抗体的分子量较小,可以构建多价或多特异性CAR,实现对抗原的精准靶向。
Smart Images

Figure BDA0005070999600000051 
Figure BDA0005070999600000061 
Figure BDA0005070999600000081
Abstract
Description
Technical Field
[0001] This invention relates to the field of immunology, and in particular to nanobodies targeting CD276 and their applications. Background Technology
[0002] CD276 (B7-H3) is a protein belonging to the B7 family. The B7 family is a group of immunomodulatory ligands that regulate T cell activation and differentiation, and are expressed in acquired immune cells, innate immune cells, and various cancer tissues. B7-H3 (CD276) is a type I transmembrane protein, belonging to the B7 family of immune co-stimulatory and co-inhibitory proteins, and its ligands are not yet known. B7-H3 was first discovered and identified as a member of the B7 family in 2001; at the same time, it was also confirmed that B7-H3 shares 20%-27% similarity with other family members. The B7-H3 protein is encoded by the chromosome 15q24 gene and structurally consists of 316 amino acids, including an extracellular domain, a transmembrane domain, and a short intracellular domain. The intracellular domain of the B7-H3 protein is very short, and no known signaling motif has been found. Furthermore, due to exon repetitions, the human B7-H3 protein contains one or two pairs of identical extracellular domains, resulting in two isotypes: 2IgB7-H3 consists of a pair of immunoglobulin variable region (IgV)-like and immunoglobulin constant region (IgC)-like extracellular domains; 4IgB7-H3 contains two pairs of identical IgV-like and IgC-like extracellular domains, and is also the major isotype in human cells. Studies have found that B7-H3 is a co-stimulatory / co-inhibitory molecule, exhibiting activity against CD4+. + and CD8 + As a co-stimulatory molecule, B7H3 signaling induces cellular immunity, promotes the secretion of cytokines such as IFN-γ, IL-8, and TNF-α, and enhances CD8+. + T-cell cytotoxicity; additionally, it can inhibit Treg cells, allowing tumors to evade the immune response. This mechanism may be related to three major signaling pathways: NFAT, NFkB, and AP-1 factors, and T-cell surface receptors regulating gene transcription. B7H3 also plays a role in regulating NK cells. B7-H3 is highly expressed in multiple tumors, including lung cancer, colorectal cancer, pancreatic cancer, liver cancer (e.g., hepatocellular carcinoma), cholangiocarcinoma, kidney cancer, bladder cancer, cervical cancer, esophageal cancer, head and neck cancer, prostate cancer, breast cancer, ovarian cancer, brain cancer (e.g., neuroblastoma or glioblastoma), pediatric cancers (e.g., osteosarcoma, neuroblastoma, rhabdomyosarcoma, or Ewing's sarcoma), melanoma, and mesothelioma, making it a promising drug target for solid tumors. Current drug research targeting B7-H3 involves multiple areas, including small molecule drugs, antibodies, ADCs, and CAR-T / NK cells.
[0003] Nanobodies, discovered in 1989 by Belgian scientists, are variable regions (VHHs) containing only heavy-chain antibody HCAbs from the camelid family. Also known as single-domain antibodies, they are highly sought after due to their small size, simple structure, high antigen-binding affinity, and high stability under extreme conditions. Therefore, nanobodies have attracted considerable interest in various research fields, particularly in the diagnosis and treatment of diseases.
[0004] The disadvantages of existing technologies include: (1) Traditional single-chain or double-chain antibodies have large molecular weights and strong immunogenicity, which makes them prone to heavy-light chain mismatch. In particular, when single-chain antibodies are used in CAR-T / NK, the heavy-light chain mismatch leads to CAR structure aggregation, which causes spontaneous depletion of CAR-T / NK and reduces the function of CAR-T / NK; (2) For solid tumor cells, the CAR-T constructed by existing technologies (CN114729041A) needs to be at an extremely high effector-to-target ratio (up to 50:1) to achieve a high tumor killing effect; (3) The antibody screening methods of existing technologies are mainly based on phage libraries, and there are relatively few types of antibodies. Summary of the Invention
[0005] In view of this, the present invention provides a CD276-targeting nanobody and its application. The present invention uses human CD276 antigen protein to immunize alpacas, obtaining peripheral blood PBMCs, then retrieving the nanobody gene, constructing a phage library, and finally obtaining antibody sequences with high antigen affinity through single B cell antibody screening technology and phage library screening technology. The discovered antibody sequences are then applied to CAR-T therapy. In vitro and in vivo efficacy studies in animals show that the obtained antibody sequences are suitable for various solid tumor indications, exhibiting significant anti-tumor effects in lung cancer, colorectal cancer, and pancreatic cancer. The antibody sequences of the present invention can be applied to the development of antibody drugs, cell therapy drugs, and ADC drugs.
[0006] To achieve the above-mentioned objectives, the present invention provides the following technical solution:
[0007] The present invention provides a nanobody targeting CD276, wherein the variable region of the amino acid sequence of the nanobody includes a complementarity-determining region (CDR); the CDR includes CDR1, CDR2 and CDR3.
[0008] (I) The amino acid sequences of the complementarity-determining region CDR1, the complementarity-determining region CDR2, and the complementarity-determining region CDR3 are shown in SEQ ID NO.1, SEQ ID NO.2, and SEQ ID NO.3, respectively; or
[0009] (II) A sequence in which one or more amino acids have been substituted, deleted, or added as described in (I); or
[0010] (III) An amino acid sequence that has more than 90% identity with the amino acid sequence described in (I) or (II).
[0011] In some specific embodiments of the present invention, the nanobody has:
[0012] (I) An amino acid sequence as shown in SEQ ID NO.4, SEQ ID NO.6, or SEQ ID NO.7; or
[0013] (II) A sequence in which one or more amino acids have been substituted, deleted, or added as described in (I); or
[0014] (III) An amino acid sequence that has more than 90% identity with the amino acid sequence described in (I) or (II).
[0015] The present invention also provides CAR molecules, including the nanobody.
[0016] In some specific embodiments of the present invention, the CAR molecule comprises, from the 5' end to the 3' end, the promoter SFFV, the signal peptide CD8a SP, the nanobody, CD8a Hinge&TM, the intracellular co-stimulatory domain 4-1BB, and the signal transduction domain CD3ζ.
[0017] The nucleotide sequence of the promoter SFFV is shown in SEQ ID NO.8; the amino acid sequence of the signal peptide CD8a SP is shown in SEQ ID NO.9; the amino acid sequence of CD8a Hinge&TM is shown in SEQ ID NO.10; the amino acid sequence of the intracellular co-stimulatory domain 4-1BB is shown in SEQ ID NO.11; and the amino acid sequence of the signal transduction domain CD3ζ is shown in SEQ ID NO.12.
[0018] The present invention also provides a kit comprising any of the following:
[0019] (I) the nanobody; and / or
[0020] (II) The CAR molecule.
[0021] The present invention also provides a nucleic acid molecule encoding the nanobody or the CAR molecule.
[0022] In some specific embodiments of the present invention, the nucleic acid molecule of the nanobody has a nucleotide sequence as shown in SEQ ID NO.5.
[0023] The present invention also provides an expression vector comprising the nucleic acid molecule.
[0024] The present invention also provides a host, including the expression vector.
[0025] This invention also provides the use of any of the following in the preparation of drugs or diagnostic reagents targeting CD276:
[0026] (I) the nanobody; and / or
[0027] (II) The CAR molecule; and / or
[0028] (III) the nucleic acid molecule; and / or
[0029] (IV) the expression vector; and / or
[0030] (V), the host.
[0031] This invention also provides the use of any of the following in the preparation of antitumor drugs:
[0032] (I) the nanobody; and / or
[0033] (II) The CAR molecule; and / or
[0034] (III) the nucleic acid molecule; and / or
[0035] (IV) the expression vector; and / or
[0036] (V), the host.
[0037] In some specific embodiments of the present invention, the tumor includes one or more of the following: lung cancer, colorectal cancer, pancreatic cancer, liver cancer (e.g., hepatocellular carcinoma), bile duct cancer, kidney cancer, bladder cancer, cervical cancer, esophageal cancer, head and neck cancer, prostate cancer, breast cancer, ovarian cancer, brain cancer (e.g., neuroblastoma or glioblastoma), pediatric cancers (e.g., osteosarcoma, neuroblastoma, rhabdomyosarcoma or Ewing's sarcoma), melanoma, or mesothelioma.
[0038] The present invention also provides a drug or combination of drugs, including any of the following:
[0039] (I) the nanobody; and / or
[0040] (II) The CAR molecule; and / or
[0041] (III) the nucleic acid molecule; and / or
[0042] (IV) the expression vector; and / or
[0043] (V), the host.
[0044] In some specific embodiments of the present invention, the drug includes an antibody drug or an ADC drug.
[0045] The present invention also provides a vaccine, comprising any of the following:
[0046] (I) the nanobody; and / or
[0047] (II) The CAR molecule; and / or
[0048] (III) the nucleic acid molecule; and / or
[0049] (IV) the expression vector; and / or
[0050] (V), the host.
[0051] The present invention also provides a treatment method comprising administering any of the following to a subject:
[0052] (I) the nanobody; and / or
[0053] (II) The CAR molecule; and / or
[0054] (III) the nucleic acid molecule; and / or
[0055] (IV) the expression vector; and / or
[0056] (V), the host.
[0057] This invention provides the following beneficial effects:
[0058] (1) Compared with traditional antibodies, nanobodies are the smallest antigen-binding fragments with good solubility, simple and stable structure, strong tissue penetration, and low immunogenicity. Especially when applied to CAR-T / NK, due to their strong hydrophilicity, CARs based on nanobodies have almost no risk of aggregation. In addition, due to the small molecular weight of nanobodies, multivalent or multispecific CARs can be constructed to achieve precise targeting of antigens.
[0059] (2) This invention uses human CD276 antigen protein to immunize alpacas, obtain peripheral blood PBMCs, then retrieve nanobody genes, establish phage libraries, and finally obtain antibody sequences with high antigen affinity and richer antibody sequence diversity through single B cell antibody screening technology and phage library screening technology. Then, the discovered antibody sequences are applied to CAR-T, and the in vitro and in vivo efficacy in animals shows that the obtained antibody sequences are suitable for various solid tumor indications, and have significant anti-tumor effects in lung cancer, colorectal cancer and pancreatic cancer.
[0060] (3) For the same solid tumor cell line, the CAR-T cells constructed by the antibody sequence of the present invention can effectively kill tumor cells under the condition of low effector-to-target ratio. The antibody sequence of the present invention can be applied to the development of antibody drugs, cell therapy drugs, ADC drugs, etc. Attached Figure Description
[0061] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the accompanying drawings used in the description of the embodiments or the prior art will be briefly introduced below.
[0062] Figure 1 The diagram shows the binding dynamics curve of antibody F22509704-CHO to antigen.
[0063] Figure 2 This diagram shows the structure of the CD276 CAR.
[0064] Figure 3 Indicates the percentage of CAR-T positive cells;
[0065] Figure 4 The killing ability of HCT116 luc cells was detected.
[0066] Figure 5 This demonstrates the killing ability of A549-luc cells;
[0067] Figure 6 The killing ability of PANC-1luc cells was detected.
[0068] Figure 7 The killing ability of BxPC-3luc cells was detected.
[0069] Figure 8 This shows the IFN-γ release level after SDT-NK016 CAR-T cells and target cells HCT116 luc were co-cultured overnight;
[0070] Figure 9 This shows the IFN-γ release level after SDT-NK016 CAR-T cells and target cells A549 luc were co-cultured overnight;
[0071] Figure 10 This shows the amount of IFN-γ released after SDT-NK016 CAR-T cells and target cells PANC-1luc were co-cultured overnight.
[0072] Figure 11 This shows the IFN-γ release level after SDT-NK016 CAR-T cells and target cells BxPC-3luc were co-cultured overnight.
[0073] Figure 12This shows the IL-2 release level after SDT-NK016 CAR-T cells and target cells HCT116 luc were co-cultured overnight;
[0074] Figure 13 The amount of IL-2 released after overnight co-culture of SDT-NK016 CAR-T cells and target cells A549 luc cells is shown.
[0075] Figure 14 This shows the amount of IL-2 released after SDT-NK016 CAR-T cells and target cells PANC-1luc cells were co-cultured overnight.
[0076] Figure 15 The CD3+CD107a percentage of SDT-NK016 CAR-T cells and target cells HCT116 luc were shown after co-culture.
[0077] Figure 16 This shows the changes in tumor volume in the HCT116 tumor model after drug administration;
[0078] Figure 17 This shows the changes in body weight in mice after administration of HCT116 to the tumor model.
[0079] Figure 18 This shows the changes in tumor volume in the PANC-1 tumor model after drug administration;
[0080] Figure 19 This shows the changes in body weight in mice after administration of PANC-1 to a tumor model.
[0081] Figure 20 A schematic diagram of the humanized CD276 CAR structure;
[0082] Figure 21 Detection of the killing ability of humanized CD276 CAR-T cells against HCT116 luc cells;
[0083] Figure 22 Detection of the killing ability of humanized CD276 CAR-T cells against PANC-1luc cells;
[0084] Figure 23 Detection of the killing ability of humanized CD276 CAR-T cells against A549 luc cells;
[0085] Figure 24 The amount of IFN-γ released after co-culturing humanized CD276 CAR-T cells and target cells HCT116 luc overnight was shown.
[0086] Figure 25 The amount of IFN-γ released after co-culturing humanized CD276 CAR-T cells and target cells PANC-1luc overnight was shown.
[0087] Figure 26 The amount of IFN-γ released after co-culturing humanized CD276 CAR-T cells and target cells A549 luc overnight was shown. Detailed Implementation
[0088] This invention discloses a CD276-targeting nanobody and its applications. Those skilled in the art can refer to this document and appropriately modify the process parameters to achieve the desired results. It is particularly important to note that all similar substitutions and modifications are obvious to those skilled in the art and are considered to be included in this invention. The methods and applications of this invention have been described through preferred embodiments. Those skilled in the art can clearly modify or appropriately change and combine the methods and applications described herein without departing from the content, spirit, and scope of this invention to realize and apply the technology of this invention.
[0089] This invention uses human CD276 antigen protein to immunize alpacas to obtain natural nanobody sequences. Then, combining single-B cell screening and phage library screening, nanobody sequences different from existing technologies are obtained. Their affinity is then verified, and sequences with an affinity of 1×10⁻⁶ are selected. -8 The antibody sequences were used to design CAR structures, and their anti-tumor functions were studied through in vitro and in vivo animal experiments. The target tumor cells were mostly solid tumors, including lung cancer, colorectal cancer, and pancreatic cancer. This invention employs a single B-cell binding phage library screening method, resulting in a richer diversity of antibodies. Furthermore, the antibody sequences of this invention can also be applied to the development of antibody drugs, cell therapy drugs, and ADC drugs.
[0090] Terminology Explanation:
[0091]
[0092] The term "chimeric antigen receptor" or "CAR" as used in this article includes at least one extracellular antigen-binding domain, hinge and transmembrane region, intracellular co-stimulatory domain, and signal transduction domain.
[0093] In a specific embodiment, the chimeric antigen receptor is a CD276 nanobody that can specifically recognize CD276.
[0094] In a specific implementation, the hinge area may be selected from the hinge area of CD8.
[0095] In specific embodiments, the transmembrane structural region may be selected from the transmembrane structural domains of the following proteins: α, β, or ζ chains of T cell receptors; CD28; CD3ε; CD45; CD4; CD5; CD8; CD9; CD16; CD22; CD33; CD37; CD64; CD80; CD86; CD134; CD137; CD154; KIRDS2; OX40; CD2; CD27; LFA-1 (CD11a; CD18); I COS(CD278); 4-1BB(CD137); GITR; CD40; BAFFR; HVEM(LIGHTR); SLAMF7; NKp80(KLRF1); CD160; CD19; IL2Rβ; IL2Rγ; IL7Rα; ITGA1; VLA1; CD49a; ITGA4; IA4; CD49D; ITGA6; VLA-6; CD49f; ITGAD; CD11d; ITGA E; CD103; ITGAL; CD11a; LFA-1; ITGAM; CD11b; ITGAX; CD11c; ITGB1; CD29; ITGB2; CD18; LFA-1; ITGB7; TNFR2; DN AM1(CD226); SLAMF4(CD244; 2B4); CD84; CD96(Tactile); CEACAM1; CRTAM; Ly9(CD229); CD160(BY55); PSGL1; CD 100 (SEMA4D); SLAMF6 (NTB-A; Ly108); SLAM (SLAMF1; CD150; IPO-3); BLAME (SLAMF8); SELPLG (CD162); LTBR; PAG / Cbp; NKp44; NKp30; NKp46; NKG2D; and NKG2C. In some embodiments, the hinge region and transmembrane domain of CD8 can be selected, and the amino acid sequence is shown in SEQ ID NO.10.
[0096] In specific embodiments, the intracellular co-stimulatory domain may be selected from the signal transduction domains of the following proteins: CD27; CD28; 4-1BB (CD137); OX40; CD30; CD40; PD-1; ICOS. In some embodiments, 4-1BB may be selected, with the amino acid sequence shown in SEQ ID NO.11.
[0097] In specific embodiments, the signal transduction domain may be selected from the signal transduction domains of the following proteins: CD3ζ; CD3γ; CD3δ; CD3ε; FcRγ (FCER1G); FcRβ (FcεR1b); CD79a; CD79b; FcγRIIa. In some embodiments, human CD3ζ (amino acid sequence as shown in SEQ ID NO:12) may be selected.
[0098] The sequence information involved in this invention is as follows:
[0099] 1. The amino acid sequence of the CDR region of the F22509704-CHO antibody
[0100] Table 1. Amino acid sequence of the CDR region of F22509704-CHO antibody.
[0101]
[0102] 2. Amino acid sequence of F22509704-CHO antibody
[0103] SEQ ID NO.4: QVQLVESVGGLVQAGGSLRLSCAASGSIPSIYTMGWYRQAPGKQR EFVASIVNEGIPGYAGSVKGRFTISRDLTKKTIYLQMNSLKPEDTAVYYCAFATYYGLGD PRYWGQGTQVTVSS
[0104] 3. Nucleotide sequence of antibody F22509704-CHO
[0105] SEQ ID NO.5: CAGGGTGCAGCTGGTGGAGAGCGTAGGAGGGTTGGTGCAGGCCG GTGGCTCGCTTCGGCTGTCATGCGCTGCGAGTGGTTCTATCCCCTCTATCTACACTATGGGCTGGTACCGCCAGGCACCCGGAAAACAAAGGGAGTTCGTCGCCAGCATTGTCAACGAGGGCATCCCGGGCTACGCGGGGAGCGTGAAGGGCCGCTT CACCATCTCCCGCGACCTGACTAAGAAGACAATTTACCTGCAGATGAACTCCCTGAAGCCTGAAGACACGGCCGTGTACTACTGTGCTTTTGCCACCTATTACGGCCTCGGTGATCCACGTTATTGGGGCCAGGGCACCCAGGTTACCGTGTCCTCC
[0106] 4. The amino acid sequence of the HU1156-hVHH2 antibody is as follows:
[0107] SEQ ID NO.6: EVQLVESGGGLVQPGGSLRLSCAASGFTPSIYTMGWYRQAPGKGR EFVASIVNEGIPGYAGSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAFATYYGLG DPRYWGQGTLVTVSS
[0108] 5. The amino acid sequence of the HU1156-hVHH4 antibody is as follows:
[0109] SEQ ID NO.7: QVQLVESGGGLVQPGGSLRLSCSASGFTPSIYTMGWYRQAPGKGR EFVASIVNEGIPGYAGSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAFATYYGLG DPRYWGQGTLVTVSS
[0110] 6. SFFV promoter nucleotide sequence
[0111] SEQ ID NO.8: GTAACGCCATTTTGCAAGGCATGGAAAAATACCAAACCAAGAA TAGAGAAGTTCAGATCAAGGGCGGGTACATGAAAATAGCTAACGTTGGGCCAAACAGGATATCTGCGGTGAGCAGTTTCGGCCCCGGCCCGGGGCCAAGAACAGATGGTCACCGCAGTTTCGGCCCCGGCCCGAGGCCAAGAACAGATGGTCCCCAGATATGGCCCAACCCTCAGCAGTTTC TTAAGACCCATCAGATGTTTCCAGGCTCCCAAGGACCTGAAATGACCCTGCGCCTTATTTGAATTAACCAATCAGCCTGCTTCTCGCTTCTGTTCGCGCGCTTCTGCTTCCCGAGCTCTATAAAAGAGCTCACAACCCCTCACTCGGCGCGCCAGTCCTCCGACAGACTGAGTCGCCCGGG
[0112] 7. Signal peptide CD8a SP amino acid sequence
[0113] SEQ ID NO.9:MALPVTALLLPLALLLHAARP
[0114] 8. CD8a Hinge&TM amino acid sequence
[0115] SEQ ID NO.10:TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVIT
[0116] 9. 4-1BB amino acid sequence
[0117] SEQ ID NO.11:KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL
[0118] 10. CD3ζ amino acid sequence
[0119] SEQ ID NO.12: RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDP EMGGKPQRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATK DTYDALHMQALPPR
[0120] Unless otherwise specified, the raw materials and reagents used in the CD276-targeting nanobody and its application provided by this invention are all commercially available.
[0121] The present invention will be further illustrated below with reference to the embodiments:
[0122] Example 1: VHH Screening Targeting CD276
[0123] 1. Construction of an alpaca immune and VHH antibody library
[0124] The extracellular domain of human CD276 (amino acids 29-466 of NP_001019907) from the full-length human CD276 antigen protein (NP_001019907) was fused with human IgG1 Fc and His tag, respectively, to construct fusion proteins CD276-hFc (Baiying, catalog number B21843202) and CD276-His (Baiying, catalog number B21843201). Alpacas were subcutaneously immunized with the CD276-hFc and CD276-His fusion proteins four times. After immunization, peripheral blood PBMCs were collected from alpacas, and a VHH antibody expression library was constructed using a microfluidic antibody screening method. Simultaneously, a phage VHH antibody library was also constructed.
[0125] 2. VHH antibody screening, expression, and affinity determination
[0126] Three rounds of solid-phase panning were performed on the VHH antibody library and phage screening library constructed by microfluidic methods. Output / input and phase pool ELISA showed that specific enrichment of sequences occurred as panning progressed. Antigens were screened using B7H3 / His, and positive clones were screened by ELISA. A total of 528 single clones were picked, resulting in 192 positive clones. Sequencing yielded 27 unique sequences. Mammalian expression of these unique sequences (VHH-human Fc) was performed, and the purified antibodies were subjected to Binding ELISA and Biacore affinity assays (Biacore 8K, Cytiva brand) to screen for antibody sequences with good affinity constants. Figure 1 ), numbered F22509704-CHO.
[0127] The Binding ELISA detection method is as follows:
[0128] Closed 3% BSA, 250 μL / well, 37℃ for 1 hour Primary resistance VHH-HuFc, 10 μg / mL for the first well, serially diluted 3-fold, blank for the last well. Secondary antibody Human Fc-HRP(1:10000), 100μL / well, 37℃, 1h Color developer termination TMB, 100 μL / well, develop color in the dark for 5 min, 1M HCl, 50 μL / well, terminate the reaction. reading The OD450 absorbance value was read using an ELISA reader.
[0129] The Biacore affinity testing method should be performed in accordance with the instrument's instruction manual.
[0130] Table 2 EC50 of F22509704-CHO expression antibody
[0131] F22509704-CHO 0.1004
[0132] Table 3. Affinity constant KD(M) of F22509704-CHO
[0133] F22509704-CHO 9.00E-08
[0134] Example 2: Preparation of CD276 CAR-T
[0135] 1. Construction of CAR plasmid targeting CD276
[0136] The F22509704-CHO nanobody sequence screened in Example 1 was amplified by PCR and cloned into the pCDH-EF1-eGFP plasmid vector (Addgene, #104834) via homologous recombination to construct the CD276 CAR plasmid. Figure 2 The constructed plasmid was designated SDT-NK016. The transformed competent E. coli cells were then plated onto a medium containing ampicillin and cultured. Positive clones were picked and sequenced. Correct sequencing indicated successful construction of the CD276-CAR plasmid.
[0137] Table 4. Structural Composition of CD276 CAR
[0138]
[0139] 2. CD276 CAR virus packaging
[0140] Reagent preparation: Take the PEI MAX, plasmids, culture media and other reagents required for the experiment out of the refrigerator in advance and let them return to room temperature for later use.
[0141] Transfection: Prepare the PEI / DNA complex. Add the CD276 CAR plasmid obtained in step 1, the helper plasmid psPAX2 (Gag-pol, Addgene#12260), and the envelope plasmid pMD2.G (VSV G, Addgene#12259) sequentially to DPBS (or opti-MEM), mix thoroughly by pipetting, and add PEI MAX at 3 times the plasmid mass. Mix well and incubate at room temperature for 15 min. Add the DNA / PEI complex dropwise to HEK293T cells and mix thoroughly. Change the medium after 6–8 hours of culture. Collect the viral supernatant twice, at 48 h and 72 h post-transfection, and store temporarily at 4°C. Centrifuge the virus to remove cell debris, retain the supernatant, centrifuge overnight to concentrate, remove the supernatant, resuspend the precipitate in an appropriate amount of viral cryopreservation buffer to obtain the concentrated viral solution, and store at -80°C for later use.
[0142] 3. CAR-T cell preparation
[0143] T cell sorting: PBMCs (peripheral blood mononuclear cells) from the donor, preserved in liquid nitrogen, were rapidly thawed in a 37°C water bath, added to complete culture medium (KBM581 medium + IL2 (200 IU / ml) + IL7 (10 ng / ml) + IL15 (10 ng / ml), centrifuged to remove the cryopreservation solution, resuspended in DPBS containing 1% HSA, counted, and the required amount of magnetic beads was calculated. The magnetic beads were washed twice with DPBS containing 1% HSA, then PBMCs were added to the magnetic beads. After co-incubation for 30 min on a three-dimensional mixer, the supernatant (NK cells) and magnetic beads (T cells) were separated using a magnetic rack. The magnetic beads were resuspended in culture medium, counted, and the sorting effect was detected by flow cytometry.
[0144] Transducing T cells: Mix 1 mL of CD276 CAR virus solution (prepared in step 2) with the corresponding volume of the transduction aid Novonectin and incubate at 37°C for 30 min; add T cells cultured to the second day, centrifuge at 32°C and 800g for 90 min, and continue to culture in an incubator. Change the medium on the second day.
[0145] CAR+ assay: Cells at approximately 5E5 cells were collected in 1.5 mL EP tubes, washed once with 1 mL FACS buffer, centrifuged to remove the supernatant, and 0.5 μL of primary antibody was added to each tube. The tubes were incubated at 4°C in the dark for 20 min, washed again, and resuspended in FACS buffer. The percentage of positive cells was then measured. The results showed that the percentage of positive cells was 57.46%. Figure 3 ).
[0146] Example 3: Preparation of target cells from different tumor sources
[0147] 1. Detection of CD276 expression levels on target cells from different tumor origins by flow cytometry.
[0148] Take 5×10 5 ~1×10 6 Target cells from different tumor sources were placed in 1.5 mL EP tubes, washed with 1 mL FACS Buffer (1% FBS, diluted with DPBS), centrifuged at 1800 rpm to remove the supernatant, and 1 μL of flow cytometry detection antibody PE anti-human CD276 (B7-H3) Antibody (Biolegend, #351004) was added. The mixture was vortexed and incubated at 4°C in the dark for 20 min. The cells were washed once with FACS Buffer, centrifuged, resuspended in FACS Buffer, and then analyzed for CD276 expression levels.
[0149] Test results:
[0150] Table 5. CD276 expression in four tumor cell lines.
[0151] HCT116 Human colon cancer cells Chinese Academy of Sciences Cell Bank 98% A549 Human lung cancer cells Chinese Academy of Sciences Cell Bank 36% PANC-1 Human pancreatic cancer cells Chinese Academy of Sciences Cell Bank 71% BxPC-3 Human in situ pancreatic cancer cells Chinese Academy of Sciences Cell Bank 22.3%
[0152] 2. Construct a tumor cell line overexpressing luciferase (luc) and detect its expression level.
[0153] The purpose of constructing a luciferase-overexpressing tumor cell line was to conduct in vitro CAR-T cell killing experiments. CAR-T cells and luciferase-overexpressing tumor cells were co-cultured, and a luciferase substrate was added. The surviving cells released fluorescence through an enzymatic digestion reaction. The ratio of dead to surviving cells was indirectly reflected by fluorescence readings. The method is as follows:
[0154] (1) Reagent preparation: Take the transfection reagent (Polyethylenimine L, PEI), plasmid, culture medium and other reagents required for the experiment out of the refrigerator in advance and let them return to room temperature for later use.
[0155] (2) Transfection: Prepare PEI / DNA complex. Take 2 mL of PBS (or opti-MEM) into a 15 mL centrifuge tube and add the core plasmid pCDH-CMV-CD276-EF1-Luc-T2A-Puro in sequence. This core plasmid was constructed from pCDH-CMV-MCS-EF1-Luc-T2A-Puro (Aono Gene, catalog number HG-VMH1366). Add the helper plasmid psPAX2 (Gag-pol) and the envelope plasmid pMD2.G (VSV G). Mix well by pipetting. Add PEI MAX at 3 times the mass of the plasmid, mix well, and let stand at room temperature for 15 min.
[0156] The PEI / DNA complex was added dropwise to HEK293T cells and mixed thoroughly. The culture dishes were placed in a 37°C, 5% CO2 incubator and incubated for 6–8 hours. The culture medium containing the transfection reagent was then removed and replaced with fresh complete culture medium (DMEM + 10% FBS). Viral supernatant was collected twice, at 48 h and 72 h post-transfection and temporarily stored at 4°C. The virus was centrifuged to remove cell debris, and the supernatant was retained. The mixture was then centrifuged overnight for concentration. The supernatant was removed, and the precipitate was resuspended in an appropriate amount of viral cryopreservation buffer to obtain concentrated viral solution, which was stored at -80°C for later use.
[0157] (3) Infect target cells: Add 1.5 × 10⁻⁶ cells to each well of a six-well plate. 6 Target cells were mixed with 10 μL of concentrated virus solution (activity titer approximately 1E+08TU / mL), polybrene was added at the working concentration, and the mixture was centrifuged at 32°C and 800g. The mixture was then incubated in an incubator. The medium was changed 6–8 h after infection, and the cells were then passaged and screened with puromycin to observe cell death.
[0158] (4) Target cell luc detection results: 5×10 5 Target cells were serially diluted in 4-5 wells of a 96-well plate, with culture medium used as blank wells. After adding 20 μL of one-glo reagent, the values were measured using a microplate reader. The results are shown in Table 6. The luciferase expression values of the four target cell lines were all above 10^6 at different cell numbers, meeting the requirements.
[0159] Table 6. luc expression in four tumor cell lines.
[0160] A549luc 121613253 73872140 46250295 24072883 2959 PANC-1luc 46802612 29519499 16285561 8817523 1597 HCT116luc 29309534 18703831 11490628 6762562 1821 BxPC-3luc 72395007 39915731 20214680 10287763 983
[0161] Example 4: In vitro functional verification of CD276 CAR-T cells
[0162] 1. Verification of cell killing function
[0163] Add 1×10 to each well of the 96-well whiteboard4 Target cells prepared according to the method of Example 3 were prepared in triplicate for each group. CAR-T cells were prepared according to the method of Example 2, and a control group of UTD-T cells (T cells without transduction treatment) was set up. After co-culturing CAR-T cells and target cells at different effector-to-target ratios for 20 h, luciferase substrate (one-glo) working solution was added, and the killing ratio of CAR-T cells and UTD-T cells on target cells was detected in an ELISA reader.
[0164] (1) Detection of the killing ability of HCT116 luc cells
[0165] The results of the HCT116 luc cell killing ability assay are shown below. Figure 4 Tables 7 and 8 show that, compared to the control group UTD-T, SDT-NK016 exhibited significantly different killing efficiencies against HCT116 luc cells under all effector-to-target ratio conditions (p<0.0001, ****). At an effector-to-target ratio of 4:1, SDT-NK016 achieved a killing efficiency exceeding 89%, while the control group UTD-T's killing efficiency was below 36%, meaning SDT-NK016's killing efficiency was more than twice that of UTD-T. At an effector-to-target ratio of 2:1, SDT-NK016 achieved a killing efficiency exceeding 78%, while the control group UTD-T's killing efficiency was below 24%, meaning SDT-NK016's killing efficiency was more than three times that of UTD-T.
[0166] Table 7. Killing efficiency of SDT-NK016 CAR-T cells against target cells HCT116 luc
[0167]
[0168] Table 8. Results of significance analysis of the killing efficiency of SDT-NK016 CAR-T cells against target cells HCT116 luc.
[0169]
[0170]
[0171] (2) Detection of the killing ability of A549-luc cells
[0172] The results of the killing ability assay for A549-luc cells are shown below. Figure 5 Tables 9 and 10 show that, compared with the control group UTD-T, SDT-NK016 exhibited significantly different killing efficiencies against A549 cells under all effector-to-target ratio conditions (p<0.0001, ****). At an effector-to-target ratio of 4:1, SDT-NK016 achieved a killing efficiency exceeding 80%, while the control group UTD-T showed no killing effect on the target cells.
[0173] Table 9. Killing efficiency of SDT-NK016 CAR-T cells against target cells A549-luc
[0174]
[0175] Table 10. Results of significance analysis of the killing efficiency of SDT-NK016 CAR-T cells against target cells A549-luc.
[0176]
[0177] (3) Detection of the killing ability of PANC-1luc cells
[0178] The results of the PANC-1luc cell killing ability assay are as follows: Figure 6 As shown in Tables 11 and 12, compared with the control group UTD-T, SDT-NK016 showed significant differences in the killing efficiency of PANC-1 cells under all effector-to-target ratio conditions. At an effector-to-target ratio of 4:1, the killing efficiency of SDT-NK016 exceeded 95%, while the killing efficiency of the control group UTD-T was below 30%, meaning that the killing efficiency of SDT-NK016 was more than three times that of the control group UTD-T.
[0179] Table 11 Killing efficiency of SDT-NK016 CAR-T cells against target cells PANC-1luc
[0180]
[0181] Table 12. Results of significance analysis of the killing efficiency of SDT-NK016 CAR-T cells against target cells PANC-1luc.
[0182]
[0183] (4) Detection of the killing ability of BxPC-3luc cells
[0184] Results of BxPC-3luc cell killing ability assay Figure 7 As shown in Tables 13 and 14, compared with the control group UTD-T, SDT-NK016 showed significant differences in the killing efficiency of target cells BxPC-3 under all effector-to-target ratio conditions (p<0.0001, ****). At an effector-to-target ratio of 1:1, the killing efficiency of SDT-NK016 exceeded 98%, while the killing efficiency of the control group UTD-T was below 20%, meaning the killing efficiency of SDT-NK016 was more than four times that of the control group UTD-T.
[0185] Table 13. Killing efficiency of SDT-NK016 CAR-T cells against target cells BxPC-3luc
[0186]
[0187] Table 14. Results of significance analysis of the killing efficiency of SDT-NK016 CAR-T cells against target cells BxPC-3luc.
[0188]
[0189] 2. IFN-γ detection:
[0190] CAR-T cells and target cells were added to 24-well plates at a 1:1 ratio and co-cultured overnight. The culture supernatant was collected, and the IFN-γ content in the supernatant was detected by ELISA. The detection method was performed according to the ACRO kit instructions (human IFN-γ, #CRS-A017).
[0191] (1) HCT116 luc cells
[0192] The results are as follows Figure 8 As shown in Table 15, the results indicate that after overnight co-culture of SDT-NK016 CAR-T cells and target cells HCT116 luc, the IFN-γ release reached over 8500 pg / mL, while the IFN-γ release of UTD-T cells and target cells HCT116 luc was only around 210 pg / mL. The IFN-γ release of SDT-NK016 CAR-T cells and target cells HCT116 luc after overnight co-culture was more than 40 times that of UTD-T cells.
[0193] Table 15. IFN-γ release levels after co-culturing SDT-NK016 CAR-T cells and target cells HCT116 luc
[0194]
[0195]
[0196] (2) A549 luc cells
[0197] The results are as follows Figure 9As shown in Table 16, the results indicate that after overnight co-culture of SDT-NK016 CAR-T cells and target cells A549 luc, the IFN-γ release reached over 13,000 pg / mL, while the IFN-γ release of UTD-T cells and target cells A549 luc after overnight co-culture was only around 90 pg / mL. The IFN-γ release of SDT-NK016 CAR-T cells and target cells A549 luc after overnight co-culture was more than 144 times that of UTD-T cells.
[0198] Table 16. IFN-γ release after co-culturing SDT-NK016 CAR-T cells and target cells A549 luc
[0199]
[0200] (3) PANC-1luc cells
[0201] The results are as follows Figure 10 As shown in Table 17, the results indicate that after overnight co-culture of SDT-NK016 CAR-T cells and target cells PANC-1luc, the IFN-γ release reached over 13400 pg / mL, while the IFN-γ release of UTD-T cells and target cells PANC-1luc was only around 110 pg / mL. The IFN-γ release of SDT-NK016 CAR-T cells and target cells PANC-1luc after overnight co-culture was more than 121 times that of UTD-T cells.
[0202] Table 17. IFN-γ release levels after co-culturing SDT-NK016 CAR-T cells and target cells PANC-1luc
[0203]
[0204] (4) BxPC-3luc cells
[0205] The results are as follows Figure 11 As shown in Table 18, the results indicate that after overnight co-culture of SDT-NK016 CAR-T cells and target cells BxPC-3luc, the IFN-γ release reached over 2100 pg / mL, while the IFN-γ release of UTD-T cells and target cells BxPC-3luc was only about 2 pg / mL. The IFN-γ release of SDT-NK016 CAR-T cells and target cells BxPC-3luc after overnight co-culture was more than 1050 times that of UTD-T cells.
[0206] Table 18. IFN-γ release after co-culturing SDT-NK016 CAR-T cells and target cells BxPC-3luc
[0207]
[0208] 3. IL-2 release
[0209] CAR-T cells and target cells were added to 24-well plates at a 1:1 ratio and co-cultured overnight. The culture supernatant was collected, and the IL-2 content in the supernatant was detected by ELISA. The detection method was performed according to the ACRO kit instructions (human IL-2, #CRS-B008).
[0210] (1) HCT116-luc cells
[0211] The results are as follows Figure 12 As shown in Table 19, the results indicate that after overnight co-culture of SDT-NK016 CAR-T cells and target cells HCT116 luc, the IL-2 release reached 450 pg / mL, while the IL-2 release of UTD-T cells and target cells HCT116 luc after overnight co-culture was only below 55 pg / mL. The IL-2 release of SDT-NK016 CAR-T cells and target cells HCT116 luc after overnight co-culture was more than 9 times that of UTD-T cells.
[0212] Table 19. IL-2 release after co-culturing SDT-NK016 CAR-T cells and target cells HCT116 luc
[0213]
[0214] (2) A549-luc cells
[0215] The results are as follows Figure 13 As shown in Table 20, the results indicate that after overnight co-culture of SDT-NK016 CAR-T cells and target cells A549-lucx cells, the IL-2 release reached 8000 pg / mL, while the IL-2 release of UTD-T cells and target cells A549-lucx cells after overnight co-culture was only below 1600 pg / mL. The IL-2 release of SDT-NK016 CAR-T cells and target cells A549-lucx cells after overnight co-culture was more than 5 times that of UTD-T cells.
[0216] Table 20. IL-2 release after co-culturing SDT-NK016 CAR-T cells and target cells A549-luc.
[0217]
[0218] (3) PANC-1luc cells
[0219] The results are as follows Figure 14As shown in Table 21, the results indicate that the IL-2 release from SDT-NK016 CAR-T cells and target cells PANC-1luc cells after overnight co-culture was close to 12000 pg / mL, while the IL-2 release from UTD-T cells and target cells PANC-1luc cells after overnight co-culture was only about 1700 pg / mL. The IL-2 release from SDT-NK016 CAR-T cells and target cells PANC-1luc cells after overnight co-culture was more than 7 times that of UTD-T cells.
[0220] Table 21. IL-2 release after co-culturing SDT-NK016 CAR-T cells and target cells PANC-1luc
[0221]
[0222] 4. CD107a detection
[0223] Add 1E+05 CAR+ cells and target cells from different donors to each well of a 96-well plate, with three replicates per group. Add CD107a antibody and incubate at 37°C for 1 h. Add 0.5 μL of CD3 and CD8 antibodies and incubate at 37°C for 30 min. Add diluted Golgi stop agent to each well, mix well, and incubate at 37°C for 2.5–3 h. Wash the cells once with flow cytometry buffer (FACSBuffer) and then perform flow cytometry analysis.
[0224] Add 1E+05 CAR+ cells and target cells from different donors to each well of a 96-well plate of HCT116-luc cells, with three replicates per group. Add CD107a antibody and incubate at 37°C for 1 h. Add 0.5 μL of CD3 and CD8 antibodies and incubate at 37°C for 30 min. Add diluted Golgi stop agent to each well, mix well, and incubate at 37°C for 2.5–3 h. Wash the cells once with flow cytometry buffer (FACS Buffer) and then perform flow cytometry analysis.
[0225] The results are as follows Figure 15 As shown in Figure 2 and Table 22, the results indicate that the CD3+CD107a% content of SDT-NK016 CAR-T cells and target cells HCT116-luc after co-culture reached over 61%, while the CD3+CD107a% content of UTD-T cells and target cells HCT116-luc after co-culture was approximately 2.7%. The CD3+CD107a% content of SDT-NK016 CAR-T cells and target cells HCT116-luc after co-culture was more than 22 times that of UTD-T cells.
[0226] Table 22 CD107a content of SDT-NK016 CAR-T cells and target cells HCT116 luc after co-culture
[0227]
[0228] Example 5: In vivo functional verification of CD276 CAR-T in animals
[0229] NSG mice were selected as the tumor animal model. The tumor cells used were HCT116 and PANC-1, all subcutaneous xenografts. The tumor-bearing dose for HCT116 mice was 2e6 cells / mouse, and for PANC-1 mice it was 1e7 cells / mouse. The CAR-T therapy dose for the HCT116 model was 1e7 cells / mouse, and for the PANC-1 model it was 5e6 cells / mouse. CAR-T efficacy was observed by periodically monitoring changes in tumor volume and mouse body weight. A control group was established using DPBS (phosphate-buffered saline) and a control group of UTD-T cells (untransduced T cells).
[0230] 1. HCT116 tumor model
[0231] 1.1 Changes in tumor volume after drug administration
[0232] The results are as follows Figure 16 As shown in Table 23, the SDT-NK016 group showed a significant difference compared to the DPBS control group (p<0.0001, ****), indicating that the SDT-NK016 group had a significant tumor suppression effect.
[0233] Table 23. Tumor volume measurement for HCT116
[0234]
[0235] 1.2 Changes in mouse body weight after drug administration
[0236] The results are as follows Figure 17 As shown in Table 24, compared with the DPBS control group, there was no significant difference in the weight change of mice in the CAR-T experimental group, indicating that CAR-T is relatively safe for mice.
[0237] Table 24 HCT116 Weight Measurement Data
[0238]
[0239] 2. PANC-1 tumor model
[0240] 2.1 Changes in tumor volume after drug administration
[0241] The results are as follows Figure 18As shown in Table 25, the SDT-NK016 group showed a significant difference compared to the DPBS control group (p<0.0001, ****), indicating that the SDT-NK016 group had a significant tumor-suppressive effect.
[0242] Table 25 PANC-1 Tumor Volume Measurement
[0243]
[0244] 2.2 Changes in mouse body weight after drug administration
[0245] The results are as follows Figure 19 As shown in Table 26, compared with the DPBS control group, there was no significant difference in the weight change of mice in the CAR-T experimental group, indicating that CAR-T is relatively safe for mice.
[0246] Table 26 PANC-1 Weight Measurement Data
[0247]
[0248] Example 6: Humanization Design of SDT-NK016 Camel-derived Sequence
[0249] 1.1 Experimental Methods
[0250] 1.1.1 Humanized Sequence Design
[0251] The CDR region of the antibody was defined by predictive analysis using the Kabat system. Human germline frame sequences were selected as candidate templates. The CDR grafting method was used to replace the camel-derived frame region (FR) with the selected human germline frame region (FR), retaining only the camel-derived CDR.
[0252] 1.1.2 Expression of humanized antibodies
[0253] The designed humanized heavy chain antibody gene was ligated into the human IgG1 Fc gene and cloned into expression plasmids, expressed as VHH-Fc. The plasmids were transfected into CHO cells, cultured for expression, and the culture supernatant was collected. After purification using a Protein A affinity chromatography column, antibody affinity was detected.
[0254] 1.1.3 Humanized Antibody Affinity Detection
[0255] The kinetics and affinity properties of the antibody were tested using the Biacore 8K platform.
[0256] 1.2 Experimental Results
[0257] By humanizing the parent sequence, expressing antibodies, and testing affinity, three humanized sequences that bind to the B7H3 antigen were obtained based on the parent sequence, as shown in the table below. Among them, HU1156-hVHH6 showed a significant decrease in affinity compared to the parent sequence and was not studied further. Only HU1156-hVHH2 and HU1156-hVHH4 were studied for CAR molecule construction and functional research.
[0258] Table 27 Sequence humanization results
[0259]
[0260] Example 7: Preparation of humanized CD276 CAR-T cells
[0261] Humanized CD276 CAR-T cells were prepared according to the method in Example 2, wherein the structure of the humanized CD276 CAR is as follows. Figure 20 As shown in Table 28.
[0262] Table 28 Humanized CD276 CAR Structure
[0263] SDT-NK065 5'LTR SFFV CD8a SP HU1156-hVHH2 CD8a hinge&TM 4-1BB CD3ζ 3'LTR SDT-NK066 5'LTR SFFV CD8a SP HU1156-hVHH4 CD8a hinge&TM 4-1BB CD3ζ 3'LTR
[0264] Example 8: In vitro functional validation of humanized CD276 CAR-T cells
[0265] The humanized CD276 CAR-T cells prepared in Example 6 were subjected to cell killing function verification and IFN-γ content detection according to the method of Example 4.
[0266] 1. Verification of cell killing function
[0267] (1) Detection of the killing ability of HCT116 luc cells
[0268] The results are as follows Figure 21 As shown in Tables 29 and 30, compared with the UTD-T group, SDT-NK065 and SDT-NK066 showed significant differences in the killing effect on target cells (p<0.0001, ****). At an effector-to-target ratio of 2:1, the killing efficiencies of SDT-NK065 and SDT-NK066 reached over 76% and 80%, respectively, while the killing efficiency of UTD-T was only about 12%. Table 29: Killing efficiency of SDT-NK065 CAR-T cells and SDT-NK066 CAR-T cells against HCT116 luc target cells under different effector-to-target ratios.
[0269]
[0270]
[0271] Table 30. Results of significance analysis
[0272]
[0273] (2) Detection of the killing ability of PANC-1luc cells
[0274] The results are as follows Figure 22 As shown in Tables 31 and 32, both SDT-NK065 and SDT-NK066 showed significant differences in cell killing activity compared to the UTD-T group (p<0.0001, ****). At an effector-to-target ratio of 4:1, the killing efficiencies of SDT-NK065 and SDT-NK066 reached over 87% and 92%, respectively, while the killing efficiency of UTD-T was only around 16%.
[0275] Table 31 Killing efficiency of SDT-NK065 CAR-T cells and SDT-NK066 CAR-T cells against PANC-1luc target cells under different effector-to-target ratios.
[0276]
[0277] Table 32 Results of significance analysis
[0278]
[0279] (3) Detection of the killing ability of A549 luc cells
[0280] The results are as follows Figure 23 As shown in Tables 33 and 34, both SDT-NK065 and SDT-NK066 showed significant differences in cell killing activity compared to the UTD-T group (p<0.0001, ****). At an effector-to-target ratio of 2:1, the killing efficiencies of SDT-NK065 and SDT-NK066 reached over 87% and 70%, respectively, while the killing efficiency of UTD-T was only around 31%.
[0281] Table 33. Killing efficiency of SDT-NK065 CAR-T cells and SDT-NK066 CAR-T cells against A549 luc target cells under different effector-to-target ratios.
[0282]
[0283] Table 34. Results of significance analysis
[0284]
[0285]
[0286] 2. IFN-γ release
[0287] (1) HCT116 luc cells
[0288] The results are as follows Figure 24 As shown in Tables 35 and 36, the results indicate that after overnight co-culture of SDT-NK065 CAR-T cells, SDT-NK066 CAR-T cells, and target cells HCT116 luc, the IFN-γ release levels reached over 2000 pg / mL and 2200 pg / mL, respectively. In contrast, after overnight co-culture of UTD-T cells and target cells HCT116 luc, the IFN-γ release levels were only around 48 pg / mL. Furthermore, the IFN-γ release levels of SDT-NK016 CAR-T cells, SDT-NK066 CAR-T cells, and target cells HCT116 luc after overnight co-culture were 41 times and 45 times higher than those of UTD-T cells, respectively.
[0289] Table 35. IFN-γ release after co-culturing SDT-NK065 CAR-T cells, SDT-NK066 CAR-T cells, and target cells HCT116 luc.
[0290]
[0291] Table 36. Results of significance analysis
[0292]
[0293] (2) PANC-1luc cells
[0294] The results are as follows Figure 25 As shown in Tables 37 and 38, the results indicate that after overnight co-culture of SDT-NK065 CAR-T cells, SDT-NK066 CAR-T cells, and target cells PANC-1luc, the IFN-γ release levels reached over 2700 pg / mL and 4000 pg / mL, respectively. In contrast, the IFN-γ release levels of UTD-T cells and target cells PANC-1luc after overnight co-culture were only around 120 pg / mL. Furthermore, the IFN-γ release levels of SDT-NK016 CAR-T cells, SDT-NK066 CAR-T cells, and target cells PANC-1luc after overnight co-culture were 22 times and 33 times higher than those of UTD-T cells, respectively.
[0295] Table 37 IFN-γ release levels after co-culturing SDT-NK065 CAR-T cells, SDT-NK066 CAR-T cells, and target cells PANC-1luc
[0296]
[0297] Table 38 Significance Analysis
[0298]
[0299] (3) A549 luc cells
[0300] The results are as follows Figure 26 As shown in Tables 39 and 40, the results indicate that after overnight co-culture of SDT-NK065 CAR-T cells, SDT-NK066 CAR-T cells, and target cells A549 luc, the IFN-γ release levels reached over 2300 pg / mL and 9000 pg / mL, respectively. In contrast, after overnight co-culture of UTD-T cells and target cells A549 luc, the IFN-γ release levels were only around 140 pg / mL. Furthermore, the IFN-γ release levels of SDT-NK016 CAR-T cells, SDT-NK066 CAR-T cells, and target cells A549 luc after overnight co-culture were 16 times and 64 times higher than those of UTD-T cells, respectively.
[0301] Table 39. IFN-γ release levels after co-culturing SDT-NK065 CAR-T cells, SDT-NK066 CAR-T cells, and target cells A549
[0302]
[0303] Table 40. Results of significance analysis
[0304]
[0305] The above description is only a preferred embodiment of the present invention. It should be noted that for those skilled in the art, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.
Claims
1. A nanobody targeting CD276, characterized in that, The variable region of the amino acid sequence of the nanobody includes a complementarity-determining region (CDR); the CDR includes CDR1, CDR2 and CDR3. The amino acid sequences of the complementarity-determining regions CDR1, CDR2, and CDR3 are shown in SEQ ID NO.1, SEQ ID NO.2, and SEQ ID NO.3, respectively.
2. The nanobody as described in claim 1, characterized in that, The nanobody has an amino acid sequence as shown in SEQ ID NO.4, SEQ ID NO.6 or SEQ ID NO.
7.
3. A CAR molecule, characterized in that, Including the nanobodies as described in claim 1 or 2.
4. A reagent kit, characterized in that, Includes any of the following: (I) The nanobody as described in claim 1 or 2; and / or (II) The CAR molecule as described in claim 3.
5. A nucleic acid molecule encoding a nanobody as described in claim 1 or 2 or encoding a CAR molecule as described in claim 3.
6. An expression carrier, characterized in that, Including the nucleic acid molecules as described in claim 5.
7. The host, characterized in that, Including the expression vector as described in claim 6.
8. Any of the following applications in the preparation of detection reagents targeting CD276: (I) The nanobody as described in claim 1 or 2; and / or (II) The CAR molecule as described in claim 3; and / or (III) The nucleic acid molecule as described in claim 5; and / or (IV) The expression vector as described in claim 6; and / or (V) The host as described in claim 7.
9. Any of the following applications in the preparation of antitumor drugs: (I) The nanobody as described in claim 1 or 2; and / or (II) The CAR molecule as described in claim 3; and / or (III) The nucleic acid molecule as described in claim 5; and / or (IV) The expression vector as described in claim 6; and / or (V) The host as described in claim 7; The tumor expressed CD276 molecules; The tumor is one or more of the following: lung cancer, colorectal cancer, pancreatic cancer, liver cancer, bile duct cancer, kidney cancer, bladder cancer, cervical cancer, esophageal cancer, head and neck cancer, prostate cancer, breast cancer, ovarian cancer, brain cancer, pediatric cancer, melanoma, or mesothelioma.
10. A drug, characterized in that, Includes any of the following: (I) The nanobody as described in claim 1 or 2; and / or (II) The CAR molecule as described in claim 3; and / or (III) The nucleic acid molecule as described in claim 5; and / or (IV) The expression vector as described in claim 6; and / or (V) The host as described in claim 7.
Citation Information
Patent Citations
High affinity nanoantibodies targeting B7H3 (CD276) for treatment of various solid tumors
CN114729041A
Amino acid sequences directed against RANK-l and polypeptides comprising the same for the treatment of bone diseases and disorders
CN101796072A
Novel anti-presepsin antibody
CN106255751A
